Pharma Mar SA (PHMMF)
OTHER OTC:PHMMF
PHMMF Stock Chart & Stats
$103.48
$0.00(0.00%)
At close: 4:00 PM EST
$103.48
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$77.10 - $112.15
Previous CloseN/A
Volume3.60K
Average Volume (3M)37.00
Market Cap
$1.81B
Enterprise Value$1.56B
Total Cash (Recent Filing)$167.22M
Total Debt (Recent Filing)$49.41M
Price to Earnings (P/E)17.2
Beta0.90
Next Earnings
Apr 23, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)3.85
Shares Outstanding18,000,000
10 Day Avg. Volume47
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue7.06
Enterprise Value/Gross Profit7.62
Enterprise Value/Ebitda23.88
Forecast
1Y Price Target
$138.50Price Target Upside33.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.77
Revenue Forecast (FY)$252.07M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationTTM cash generation strength is durable for 2–6 months: operating cash flow and a sizable cash balance provide funding optionality for launches, R&D, or buybacks without immediate reliance on external financing. This materially reduces near‑term liquidity risk and supports execution of planned commercial rollouts.
Revenue And Profitability ReboundA substantive rebound in sales and operating profit reflects improved commercial traction and diversified revenue (sales, royalties, licensing). Sustained higher margins and expanding revenue base increase structural earnings power and provide runway to absorb increased commercial investment while funding pipeline milestones.
Regulatory And Pipeline CatalystsPotential EU approval and multiple upcoming trial readouts materially expand addressable markets and future royalty streams. These structural catalysts, if realized, create recurring commercial revenue channels and de-risk single‑product dependence by layering new indications and products into longer‑term commercial forecasts.
Bears Say
Earnings And Cash-Flow VolatilityHistoric swings in profitability and cash generation reduce predictability of free cash flow and complicate multi-year planning. Volatility can pressure credit metrics, raise financing costs, and makes sustained investment in commercial launches and R&D riskier absent consistently repeatable cash conversion.
High Reliance On External PartnersHeavy dependence on third-party licensees for regulatory filings, commercialization and disclosure limits PharmaMar's control of timing, pricing and inventory. Partner execution risk can delay revenues, mute upside from approvals, and amplify downside if partner priorities shift or performance disappoints.
European Pricing/Reimbursement & Rising Commercial CostsUncertain European reimbursement outcomes can materially delay or reduce launch revenue after approval. Simultaneously planned meaningful increases in commercial spend will pressure margins until volume and pricing are secured, raising execution risk and sensitivity to unfavorable pricing decisions or slower uptake.
Pharma Mar SA News
PHMMF FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was $77.10 and its highest was $112.15 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is $1.81B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Apr 23, 2026 which is in 26 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Feb 27, 2026. The company reported $3.849 earnings per share for the quarter, beating the consensus estimate of $3.543 by $0.306.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of $0.929 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.14.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of $3.849 in its last earnings report, beating expectations of $3.543. Following the earnings report the stock price went up 3.287%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in PHMMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$138.50 (33.84% Upside)
$138.50 (33.84% Upside)
Insider Transactions
Bought Shares
Worth $8.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.06%
12-Months-Change
Fundamentals
Return on Equity
35.36%
Trailing 12-Months
Asset Growth
28.31%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
PHMMF Company Deck
PHMMF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all PHMMF earnings summariesPHMMF Stock 12 Month Forecast
Average Price Target
$138.50
▲(33.84% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Ownership Overview
― Insiders
2.46% Mutual Funds
― Other Institutional Investors
93.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---